Follow us on LinkedIn and Twitter
DMTC works collaboratively with many innovative Australian industry, research and government partners. Our focus is on delivering enhanced defence and national security capabilities, and strengthening Australian industrial capacity. Our approach delivers outstanding achievements in research excellence and technology adoption, backed by a best-practice quality system.
A novel Q Fever vaccine is progressing to pre-clinical trials following a $1.87 million investment from the Department of Health into DMTC’s national Medical Countermeasures (MCM) Initiative.